Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug 11:12:682180.
doi: 10.3389/fimmu.2021.682180. eCollection 2021.

Sensitization and Desensitization in Vascularized Composite Allotransplantation

Affiliations
Review

Sensitization and Desensitization in Vascularized Composite Allotransplantation

Dimitrios Moris et al. Front Immunol. .

Abstract

Vascularized composite allotransplantation (VCA) is a field under research and has emerged as an alternative option for the repair of severe disfiguring defects that result from severe tissue loss in a selected group of patients. Lifelong immunosuppressive therapy, immunosuppression associated complications, and the effects of the host immune response in the graft are major concerns in this type of quality-of-life transplant. The initial management of extensive soft tissue injury can lead to the development of anti-HLA antibodies through injury-related factors, transfusion and cadaveric grafting. The role of antibody-mediated rejection, donor-specific antibody (DSA) formation and graft rejection in the context of VCA still remain poorly understood. The most common antigenic target of preexisting alloantibodies are MHC mismatches, though recognition of ABO incompatible antigens, minor histocompatibility complexes and endothelial cells has also been shown to contribute to rejection. Mechanistically, alloantibody-mediated tissue damage occurs primarily through complement fixation as well as through antibody-dependent cellular toxicity. If DSA exist, activation of complement and coagulation cascades can result in vascular thrombosis and infarction and thus rejection and graft loss. Both preexisting DSA but especially de-novo DSA are currently considered as main contributors to late allograft injury and graft failure. Desensitization protocols are currently being developed for VCA, mainly including removal of alloantibodies whereas treatment of established antibody-mediated rejection is achieved through high dose intravenous immunoglobulins. The long-term efficacy of such therapies in sensitized VCA recipients is currently unknown. The current evidence base for sensitizing events and outcomes in reconstructive transplantation is limited. However, current data show that VCA transplantation has been performed in the setting of HLA-sensitization.

Keywords: antibody-mediated rejection; burns; desensitization; face transplantation; hand transplantation; sensitization; vascular composite allotransplantation.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Desensitization strategies in VCA.

Similar articles

Cited by

References

    1. Wang J, Wu J, Moris D, Hayes B, Abraham SN, Cendales LC. Introducing a Novel Experimental Model of Bladder Transplantation in Mice. Am J Transplant (2020) 20(12):3558–66. 10.1111/ajt.15912 - DOI - PMC - PubMed
    1. Cendales L, Hardy MA. Immunologic Considerations in Composite Tissue Transplantation: Overview. Microsurgery (2000) 20(8):412–9. 10.1002/1098-2752(2000)20:8<412::AID-MICR12>3.0.CO;2-M - DOI - PubMed
    1. Moris D, Wang J, Selim MA, Song M, Stempora L, Parker W, et al. . Vascularized Composite Allotransplants as a Mechanistic Model for Allograft Rejection - An Experimental Study. Transplant Int (2021) 34(3):572–84. 10.1111/tri.13820 - DOI - PubMed
    1. Giannis D, Moris D, Cendales LC. Costimulation Blockade in Vascularized Composite Allotransplantation. Front Immunol (2020) 11:544186. 10.3389/fimmu.2020.544186 - DOI - PMC - PubMed
    1. Haas M, Sis B, Racusen LC, Solez K, Glotz D, Colvin RB, et al. . Banff 2013 Meeting Report: Inclusion of C4d-Negative Antibody-Mediated Rejection and Antibody-Associated Arterial Lesions. Am J Transplant (2014) 14(2):272–83. 10.1111/ajt.12590 - DOI - PubMed

MeSH terms